Litfulo - direct healthcare professional communication (DHPC)

ritlecitinib tosilate
DHPCHuman

Latvian is available via eTranslation, the European Commission's machine translation service.

Translate to Latvian | Important information about machine translation

Par

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Dokumenti

Direct healthcare professional communication (DHPC): Litfulo (ritlecitinib): Updated recommendations to minimise the risks of major adverse cardiovascular events, malignancy, venous thromboembolism, serious infections, and mortality

English (EN) (180.13 KB - PDF)

Pirmo reizi publicēts:
Skatīt

Key facts

Medicine name
Litfulo
Active substance
ritlecitinib tosilate
Therapeutic area (MeSH)
Alopecia Areata
Regulatory outcome
Variation
DHPC type
  • Adverse event
  • Post-authorisation measure
  • Restriction of indication
Human ATC codes
L04AF08
Dissemination date

Share this page